Molecular structure of Brinzolamide, CAS Number: 138890-62-7
Brinzolamide (CAS 138890-62-7)
CAS Number:
138890-62-7
Molecular Weight:
383.51
Molecular Formula:
C12H21N3O5S3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Brinzolamide is an inhibitor of carbonic anhydrase, an enzyme that catalyzes the reversible hydration of carbon dioxide. Brinzolamide works by reducing the production of aqueous humor in the eye, thereby decreasing the pressure within the eye. It is a sulfonamide derivative and is structurally related to acetazolamide, another carbonic anhydrase inhibitor.
Brinzolamide (CAS 138890-62-7) References
- Effects of brinzolamide on aqueous humor dynamics in monkeys and rabbits. | Toris, CB., et al. 2003. J Ocul Pharmacol Ther. 19: 397-404. PMID: 14583132
- Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension. | Croxtall, JD. and Scott, LJ. 2009. Drugs Aging. 26: 437-46. PMID: 19552495
- Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension. | Iester, M. 2008. Clin Ophthalmol. 2: 517-23. PMID: 19668749
- Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. | Lanzl, I. and Raber, T. 2011. Clin Ophthalmol. 5: 291-8. PMID: 21468336
- Development of inclusion complex of brinzolamide with hydroxypropyl-β-cyclodextrin. | Zhang, Y., et al. 2013. Carbohydr Polym. 98: 638-43. PMID: 23987393
- Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo. | Tuomela, A., et al. 2014. Int J Pharm. 467: 34-41. PMID: 24680962
- Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review. | Bakthavatchalam, M., et al. 2018. Surv Ophthalmol. 63: 329-339. PMID: 28987613
- Effects of brinzolamide on rabbit ocular blood flow in vivo and ex vivo. | Dong, YR., et al. 2018. Int J Ophthalmol. 11: 719-725. PMID: 29862168
- Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study. | Dubey, V., et al. 2020. Int J Biol Macromol. 152: 1224-1232. PMID: 31751741
- Design, optimisation and evaluation of in situ gelling nanoemulsion formulations of brinzolamide. | Bhalerao, H., et al. 2020. Drug Deliv Transl Res. 10: 529-547. PMID: 31820300
- Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension. | Lerner, SF., et al. 2019. Clin Ophthalmol. 13: 2411-2419. PMID: 31824135
- Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy. | Li, T., et al. 2020. Drug Deliv. 27: 410-421. PMID: 32133894
- Factors affecting the particle size distribution and rheology of brinzolamide ophthalmic suspensions. | Vo, A., et al. 2020. Int J Pharm. 586: 119495. PMID: 32553495
- Investigating the ocular toxicity potential and therapeutic efficiency of in situ gel nanoemulsion formulations of brinzolamide. | Talaei, S., et al. 2020. Toxicol Res (Camb). 9: 578-587. PMID: 32905229
- Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film. | Sedlak, L., et al. 2021. BMC Ophthalmol. 21: 319. PMID: 34470600
Inhibitor of:
CA III, CA IV, CA V, CA VI, CA VII, CA XII, CA XIII, CA XV, Carbonic Anhydrases, retbindin, and SLC4A7.Activator of:
CA I.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Brinzolamide, 10 mg | sc-481649 | 10 mg | $269.00 |